U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
Thymopentin is a synthetic pentapeptide which is the active site of the naturally occurring hormone thymopoietin with immunomodulating properties. Thymopentin can specifically promote the differentiation and maturation of thymic T cells and natural killer cells (NK) and enhance the function of T helper cells. thymic can achieve a two-way adjustment to the immune system by increasing the levels of intracellular cyclic adenosine monophosphate, elevating the activity of T cells, and regulating the proportions of T cell subsets. As an immunomodulating agent, Thymopentin is clinically used in the treatments of autoimmune diseases, such as e.g. atopic dermatitis, chronic lymphocytic leukemia, Sezary's syndrome, rheumatoid arthritis, as well as decreased immune competency in elder surgical patients. Due to poor membrane permeability, extensive metabolism in the GI, and extremely short half-life of 30 s, repeated injections or i.v infusions of Thymopentin are necessary which greatly restrict its clinical applications.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
PubMed

PubMed

TitleDatePubMed
Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy.
1987 Mar
Zidovudine therapy of asymptomatic HIV1-infected patients and combined zidovudine-acyclovir therapy of HIV1-infected patients with oral hairy leukoplakia.
1989 Apr
Successful interferon alpha therapy in atopic dermatitis of Besnier's prurigo pattern with normal serum IgE and blood eosinophil fraction: randomized case-controlled study.
2001 Jan 21
[Concentrations of MMP-1, TIMP-1, MMP-1/TIMP-1 and I CTP complexes in follicular fluid as related to fertilization rate in women treated with in-vitro fertilization].
2001 Mar
[Stability evaluation of thymopentin in preparation process].
2003 Apr
Analogs of RGDVY and GRGD peptides inhibit Mycobacterium kansasii phagocytosis.
2003 Aug
MS2Assign, automated assignment and nomenclature of tandem mass spectra of chemically crosslinked peptides.
2003 Aug
[Clinical trial to verify the value of the CD14(+) monocyte human leukocyte antigen DR as a marker in evaluating immunosuppression in patients with severe sepsis].
2003 Mar
Quantitative analysis with desorption/ionization on silicon mass spectrometry using electrospray deposition.
2003 Oct 15
[Controlled clinical study on 49 patients of SARS treated by integrative Chinese and Western medicine].
2003 Sep
Trypsin-catalyzed kinetically controlled synthesis of a precursor dipeptide of thymopentin in organic solvents, using a free amino acid as nucleophile.
2004 Feb
Increased radiation toxicity by enhanced apoptotic clearance of HL-60 cells in the presence of the pentapeptide thymopentin, which selectively binds to apoptotic cells.
2004 Mar 14
Chemical synthesis and application of C-terminally 5-carboxyfluorescein-labelled thymopentin as a fluorescent probe for thymopoietin receptor.
2006 Dec
Meta-analysis: the adjuvant role of thymopentin on immunological response to hepatitis B virus vaccine in end-stage renal disease.
2006 Jun 1
Immunotherapy with canarypox vaccine and interleukin-2 for HIV-1 infection: termination of a randomized trial.
2007 Jan 26
Thymic reticulo-epithelial cells: key cells of neuroendocrine regulation.
2007 Jul
[Research on thymopentin-loaded N-trimethyl chitosan nanoparticles administered through mouth].
2007 Sep
Conjugation of thymopentin (TP5) with lipoamino acid residues increases the hydrolytic stability and preserves the biological activity.
2007 Sep
[Thymopentin 5 in treatment of relapse after extended thymectomy: a randomized comparative clinical trial of 135 patients with myasthenia gravis].
2008 Aug 26
Preparation and evaluation of poly-butylcyanoacrylate nanoparticles for oral delivery of thymopentin.
2008 Jun
Expression of thymosin alpha1-thymopentin fusion peptide in Pichia pastoris and its characterization.
2008 Nov
Characterization of a new inhalable thymopentin formulation.
2009 Jun 22
[Immunomodulatory effects of thymopentin under acute and chronic inflammations in mice].
2009 Mar-Apr
Recent advances in PEG-PLA block copolymer nanoparticles.
2010 Nov 26
Preparation, characterization and in vivo pharmacodynamic evaluation of thymopentin loaded poly(lactide acid)/poly(lactide-co-glycolide acid) implants.
2010 Oct 15
Preparation of gel-core-solid lipid nanoparticle: a novel way to improve the encapsulation of protein and peptide.
2010 Sep
Patents
Name Type Language
THYMOPENTIN MONOACETATE
Common Name English
L-TYROSINE, N-(N-(N-(N2-L-ARGINYL-L-LYSYL)-L-.ALPHA.-ASPARTYL)-L-VALYL)-, MONOACETATE
Common Name English
L-TYROSINE, L-ARGINYL-L-LYSYL-L-.ALPHA.-ASPARTYL-L-VALYL-, MONOACETATE (SALT)
Common Name English
Code System Code Type Description
CAS
89318-88-7
Created by admin on Sat Dec 16 09:12:52 GMT 2023 , Edited by admin on Sat Dec 16 09:12:52 GMT 2023
PRIMARY
PUBCHEM
53230082
Created by admin on Sat Dec 16 09:12:52 GMT 2023 , Edited by admin on Sat Dec 16 09:12:52 GMT 2023
PRIMARY
FDA UNII
1938Y8P51M
Created by admin on Sat Dec 16 09:12:52 GMT 2023 , Edited by admin on Sat Dec 16 09:12:52 GMT 2023
PRIMARY
EPA CompTox
DTXSID80237615
Created by admin on Sat Dec 16 09:12:52 GMT 2023 , Edited by admin on Sat Dec 16 09:12:52 GMT 2023
PRIMARY
CAS
177966-81-3
Created by admin on Sat Dec 16 09:12:52 GMT 2023 , Edited by admin on Sat Dec 16 09:12:52 GMT 2023
NON-SPECIFIC STOICHIOMETRY